Table 1.
Extranodal diffuse large B-cell lymphoma incidence (1973–2015) and incidence-based mortality (1988–2015): the SEER-9 registry database.
| Characteristic | Incidence | Incidence-based mortality | ||
|---|---|---|---|---|
| Cases, No. (%) | Rate (95% CI) | Cases, No. (%) | Rate (95% CI) | |
| Overall | 15,882 | 1.579 (1.555–1.604) | 8,776 | 1.205 (1.179–1.230) |
| Age, y | ||||
| ≤14 | 93 (0.586) | 0.041 (0.033–0.50) | 6 (0.068) | 0.004 (0.001–0.008) |
| 15–39 | 1,409 (8.872) | 0.359 (0.340–0.378) | 352 (4.011) | 0.129 (0.116–0.143) |
| 40–64 | 5,604 (35.285) | 1.742 (1.696–1.788) | 1623 (18.494) | 0.682 (0.649–0.716) |
| 65–85+ | 8,776 (55.258) | 7.230 (7.079–7.384) | 6795 (77.427) | 7.522 (7.344–7.703) |
| Sex | ||||
| Male | 8,620 (54.275) | 1.934 (1.893–1.976) | 4745 (54.068) | 1.589 (1.543–1.635) |
| Female | 7,262 (45.725) | 1.289 (1.260–1.320) | 4031 (45.932) | 0.923 (0.895–0.952) |
| Race# | ||||
| White | 13,270 (83.554) | 1.596 (1.568–1.623) | 7437 (84.742) | 1.233 (1.205–1.261) |
| Black | 967 (6.089) | 1.041 (0.974–1.111) | 491 (5.595) | 0.772 (0.7–2–0.845) |
| Other | 1,579 (9.942) | 1.797 (1.708–1.889) | 841 (9.583) | 1.235 (1.152–1.323) |
| Ann Arbor Stage* | ||||
| I/II | 9,841 (61.963) | 1.175 (1.152–1.198) | 5,377 (61.269) | 0.738 (0.718–0.758) |
| III/IV | 3,962 (24.946) | 0.474 (0.459–0.489) | 2,553 (29.091) | 0.350 (0.337–0.364) |
| Unknown | 749 (4.716) | 0.089 (0.083–0.096) | 846 (9.640) | 0.116 (0.109–0.124) |
| Site | ||||
| Head/Neck | 3,602 (22.680) | 0.359 (0.347–0.371) | 1,842 (20.989) | 0.253 (0.241–0.264) |
| Skin and soft tissue | 1,717 (10.811) | 0.171 (0.163–0.179) | 944 (10.757) | 0.130 (0.122–0.138) |
| Gastrointestinal tract | 5,430 (34.190) | 0.541 (0.527–0.556) | 3,235 (36.862) | 0.444 (0.429–0.460) |
| Genitourinary tract | 1,175 (7.398) | 0.116 (0.110–0.123) | 629 (7.167) | 0.086 (0.080–0.094) |
| Skeletal tissue | 963 (6.063) | 0.094 (0.088–0.100) | 387 (4.410) | 0.053 (0.048–0.059) |
| Respiratory system | 681 (4.288) | 0.068 (0.063–0.073) | 438 (4.991) | 0.060 (0.054–0.066) |
| Hematologic system | 733 (4.615) | 0.072 (0.067–0.078) | 378 (4.307) | 0.051 (0.046–0.057) |
| Liver/pancreas | 577 (3.633) | 0.058 (0.053–0.063) | 375 (4.273) | 0.052 (0.047–0.057) |
| Breast tissue | 423 (2.663) | 0.042 (0.038–0.047) | 223 (2.541) | 0.031 (0.027–0.035) |
| Other | 581 (3.658) | 0.058 (0.053–0.063) | 325 (3.703) | 0.044 (0.040–0.049) |
#
The sparse number of patients whose race was unknown were excluded for further evaluation in the incidence and Incidence-Based Mortality (n = 66 and n = 7, respectively) analysis. Therefore, the percentages of race in the incidence and Incidence-Based Mortality analysis do not add up to 100%.
*
The incidence cases come from the registries of the SEER-9 cancer incidence file of the US National Cancer Institute from 1973 to 2015, while the Ann Arbor Stage case has only been recorded since 1983. Therefore, the percentages of Ann Arbor stages in the incidence analysis do not add up to 100%.